IL-6 inhibitors significantly reduced the hazard ratio for relapse as well as the annualized relapse rate of the disease compared to placebo or traditional immunosuppressants. Interleukin (IL)-6 ...
Patients taking apixaban had a similar risk of major and minor bleeding events as those receiving standard of care therapy. SAN DIEGO—Apixaban therapy resulted in a low risk of venous thromboembolism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback